Ipilimumab is a drug approved for the treatment of melanoma. It works by activating the immune system to attack the tumor. Dabrafenib is a newer drug designed to stop melanoma growth by turning off BRAF, a protein activated in some melanomas, while trametinib is a new drug designed to inhibit melanoma by blocking a protein called MEK.
The combination of these drugs has the potential to be effective against melanoma. The purpose of this study is to find the optimal dose combination of ipilimumab, dabrafenib, and trametinib in patients with metastatic or inoperable melanoma that contains V600E or V600K BRAF mutations. Patients will receive either ipilimumab/dabrafenib/trametinib or ipilimumab/dabrafenib.
Dabrafenib and trametinib are pills that are taken orally (by mouth), while ipilimumab is given intravenously (by vein).